Download PDF
CC BY-NC-ND 4.0 · Laryngorhinootologie 2020; 99(S 01): S60-S106
DOI: 10.1055/a-1012-9396
Referat
Eigentümer und Copyright ©Georg Thieme Verlag KG 2019

Qualität in der Kopf-Hals-Onkologie

Quality in head neck oncology Article in several languages: deutsch | English
Susanne Wiegand
1   Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinikum Leipzig
,
Andreas Dietz
1   Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinikum Leipzig
› Author Affiliations
Further Information

Publication History

Publication Date:
16 March 2020 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Eine fachlich-qualifizierte, patienten- und bedarfsgerechte, wirtschaftliche, qualitativ hochwertige Versorgung von Patienten mit Kopf-Hals-Karzinomen ist eine Herausforderung. Basis der Qualitätsoptimierung in der deutschen Kopf-Hals-Onkologie sind qualitätsfördernde Rahmenbedingungen, wie der Nationale Krebsplan, der Ausbau klinischer Krebsregister und das Vorhandensein evidenzbasierter Leitlinien, die im Rahmen des 2008 initiierten „Leitlinienprogramms Onkologie“ erstellt wurden (S3-Leitlinien Mundhöhlenkarzinom und Larynxkarzinom). Aktuell gibt es in Deutschland 56 zertifizierte Kopf-Hals-Tumorzentren mit dem Ziel einer objektivierbaren Qualitätssteigerung der Behandlung und einer Verbesserung des Outcomes der Patienten. Verschiedene Qualitätsindikatoren wurden erarbeitet, es gibt Programme zur Qualitätssicherung der Therapie sowie innerhalb von Studien. Ziel des Referates ist es, Qualitätsstandards in der Kopf-Hals-Onkologie darzustellen.

Abstract

A professionally qualified, patient- and demand-oriented, economic, high-quality care of patients with head and neck cancer is a challenge. Quality optimization in German head and neck oncology is based on quality-enhancing framework conditions such as the National Cancer Plan, the expansion of clinical cancer registries and the existence of evidence-based guidelines that were drawn up as part of the “Oncology Guidelines Program” initiated in 2008 (S3-guidelines for oral cavity and larynx cancer). There are currently 56 certified head and neck cancer centres in Germany with the aim of objectifiably increasing the quality of treatment and improving the outcomes of patients. Various quality indicators have been developed, there are programs for quality assurance of therapy and within studies. The aim of this review is to present quality standards in head and neck oncology.

Schlüsselwörter

Kopf-Hals-Chirurgie - DKG-Zertifizierung - Qualitätsstandard - Qualitätsindikator - Patient-reported Outcome - Leitlinien
 

  • Literatur

  • 1 Lohr KN, Schroeder SA. A Strategy for Quality Assurance in Medicare. N Engl J Med 1990; 322: 707-712
    PubMedGoogle Scholar
  • 2 Bericht zum Krebsgeschehen in Deutschland 2016. Kapitel 4. Folgen von Krebserkrankungen. Robert-Koch-Institut. 2016
    PubMed
  • 3 https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Mundhoehle_Rachenkrebs/mundhoehle_rachen_node.html;jsessionid=8559195E959168467BBECD37C5E30FB2.1_cid298
    PubMed
  • 4 https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Kehlkopfkrebs/kehlkopfkrebs_node.html
    PubMed
  • 5 Donabedian A. Evaluating the quality of medical care. 1966. Milbank Q 2005; 83: 691-729
    CrossrefPubMedGoogle Scholar
  • 6 (Muster-)Berufsordnung für die in Deutschland tätigen Ärztinnen und Ärzte - MBO-Ä 1997 – in der Fassung der Beschlüsse des 114. Deutschen Ärztetages 2011 in Kiel https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/MBO_08_20112.pdf
    PubMed
  • 7 Nationaler Krebsplan https://www.bundesgesundheitsministerium.de/fileadmin/ Dateien/5_Publikationen/Praevention/Broschueren/Broschuere_Nationaler_Krebsplan.pdf
    PubMed
  • 8 Hamburgisches Krebsregister. Hamburger Krebsdokumentation 1995–1998. Hamburgisches Krebsregister, Hamburg 2001
    PubMed
  • 9 Katalinic A, Hense HW, Becker N. Krebsregistrierung in Deutschland. Onkologe 2006; 12: 1084-1093
    CrossrefPubMedGoogle Scholar
  • 10 Ministerium für Frauen, Arbeit, Gesundheit und Soziales.Morbidität und Mortalität an bösartigen Neubildungen im Saarland 1996 und 1997, Jahresbericht des Saarländischen Krebsregisters. Epidemiologisches Krebsregister Saarland, Saarbrücken. 2000
    PubMedGoogle Scholar
  • 11 De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R. EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5- a population-based study. Lancet Oncol 2014; 15: 23-34
    CrossrefPubMedGoogle Scholar
  • 12 Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn‘t. BMJ 1996; 312: 71-72
    CrossrefPubMedGoogle Scholar
  • 13 NCCN Guidelines. Head and neck cancer https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
    PubMed
  • 14 Koyfman SA, Ismaila N, Holsinger FC. Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline Summary. J Oncol Pract 2019; 15: 273-278
    CrossrefPubMedGoogle Scholar
  • 15 Quon H, Vapiwala N, Forastiere A, Kennedy EB, Adelstein DJ, Boykin H, Califano JA, Holsinger FC, Nussenbaum B, Rosenthal DI, Siu LL, Waldron JN. Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol 2017; 35: 4078-4090
    CrossrefPubMedGoogle Scholar
  • 16 Forastiere AA, Ismaila N, Lewin JS, Nathan CA, Adelstein DJ, Eisbruch A, Fass G, Fisher SG, Laurie SA, Le QT, O'Malley B, Mendenhall WM, Patel S, Pfister DG, Provenzano AF, Weber R, Weinstein GS, Wolf GT. Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018; 36: 1143-1169
    CrossrefPubMedGoogle Scholar
  • 17 Grégoire V, Lefebvre JL, Licitra L, Felip E. EHNS-ESMO-ESTRO Guidelines Working Group . Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5 v184-v186
    CrossrefPubMedGoogle Scholar
  • 18 Chan AT, Grégoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, Felip E. EHNS–ESMO–ESTRO Guidelines Working Group. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7 vii83-vii85
    CrossrefPubMedGoogle Scholar
  • 19 S3-Leitlinie Diagnostik und Therapie des Mundhöhlenkarzinoms. AWMF-Register-Nummer (007-100OL) Version 2.0 12.2012 https://www.awmf.org/uploads/tx_szleitlinien/007-100OLl_S3_Mundhöhlenkarzinom_122012-122015-abgelaufen.pdf
    PubMed
  • 20 S3-Leitlinie Diagnostik, Therapie und Nachsorge des Larynxkarzinoms. Langversion 1.0– Januar 2019, AWMF-Registernummer: 017/076OL https://www.awmf.org/uploads/tx_szleitlinien/017-076OLl_S3_Larynxkarzinom_2019-02.pdf
    PubMed
  • 21 Leitlinienprogramm Onkologie https://www.leitlinienprogramm-onkologie.de
    PubMed
  • 22 Renninger C. Living guidelines: Anspruch und Wirklichkeit in der Onkologie. https://www.coliquio.de/wissen/onkologie-kompakt-100/Living-Guidelines-100
    PubMed
  • 23 Akl EA, Meerpohl JJ, Elliott J, Kahale LA, Schünemann HJ. Living Systematic Review Network. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol 2017; 91: 47-53
    CrossrefPubMedGoogle Scholar
  • 24 Grimshaw JM, Thomas RE, MacLennan G, Ramsay CR, Vale L, Whitty P, Eccles MP, Matowe L, Shirran L, Wensing M, Dijkstra R, Donaldson C. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health technology assessment 2004; 8: 1-72
    PubMedGoogle Scholar
  • 25 Swegal WC, Herbert RJ, Eisele DW, Chang J, Bristow RE, Gourin CG. Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for laryngeal cancer. Laryngoscope. 2019; Jun 6 DOI: 10.1002/lary.28104.. [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 26 Lewis CM, Nurgalieva Z, Sturgis EM, Lai SY, Weber RS. Improving patient outcomes through multidisciplinary treatment planning conference. Head Neck 2016; 38 Suppl 1 E1820-E1825
    CrossrefPubMedGoogle Scholar
  • 27 Gourin CG, Herbert RJ, Quon H, Fakhry C, Kiess AP, Eisele DW, Frick KD. Quality of care and short and long-term outcomes of oropharyngeal cancer care in the elderly. Head Neck. 2019; Jul 11 DOI: 10.1002/hed.25869.. [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 28 Alle onkologischen S3-Leitlinien – jetzt auch als App! Forum 2019; 34: 130
    PubMed
  • 29 McGlynn EA, Asch SM. Developing a clinical performance measure. Am J Prev Med 1998; 14 (3 Suppl) 14-21
    CrossrefPubMedGoogle Scholar
  • 30 Sens B, Fischer B, Bastek A, Eckardt J, Kaczmarek D, Paschen U, Pietsch B, Rath S, Ruprecht T, Thomeczek C, Veit C, Wenzlaff P. Begriffe und Konzepte des Qualitätsmanagements – 3. Auflage. . GMS Med Inform Biom Epidemiol 2007; 3: Doc05 http://www.egms.de/en/journals/mibe/2007- 3/mibe000053.shtml
    PubMedGoogle Scholar
  • 31 Standard Operating Procedures (SOPs) http://www.ccc-netzwerk.de/arbeits-gruppen/standard-operating-procedures.html
    PubMed
  • 32 Heimpl H. Zur Bedeutung nationaler und lokaler Leitlinien für ärztliche Entscheidungen. Medizinische Klinik 2003; 98: 226-230
    CrossrefPubMedGoogle Scholar
  • 33 Cramer JD, Speedy SE, Ferris RL, Rademaker AW, Patel UA, Samant S. National evaluation of multidisciplinary quality metrics for head and neck cancer. Cancer 2017; 123: 4372-4381
    CrossrefPubMedGoogle Scholar
  • 34 Mensah J, Graeven U, Wesselmann S. Nationales Zertifizierungsprogramm Krebs. Der Onkologe 2017; 23: 711-718
    CrossrefPubMedGoogle Scholar
  • 35 Klauber J, Geraedts M, Friedrich J, Wasem J. Hrsg Krankenhaus-Report 2019. Das digitale Krankenhaus. Springer; Berlin Heidelberg:
    Google Scholar
  • 36 Deutsche Krebsgesellschaft startet Pilotprojekt zur ärztlichen Zweitmeinung. Forum. 2019 34. 230
    PubMedGoogle Scholar
  • 37 Adam H, Sibert NT, Bruns J, Wesselmann S. Krebspatienten qualitätsgesichert, multidisziplinär und evidenzbasiert versorgen: das Zertifizierungssystem der Deutschen Krebsgesellschaft. BARMER Gesundheitswesen aktuell 2018; 136-155
    PubMedGoogle Scholar
  • 38 Kennzahlenauswertung 2019. Jahresbericht der zertifizierten Kopf-Hals-Tumorzentren https://www.onkozert.de/wordpress/wp-content/uploads/2019/05/khtz_jahresbericht-2019-A1_190521.pdf?v=15484791
    PubMed
  • 39 Prognos 2018: Endbericht „Nutzen, Mehraufwand und Finanzierung von Onkologischen Spitzenzentren, Onkologischen Zentren und Organkrebszentren“. Im Auftrag der Deutschen Krebshilfe und der Deutschen Krebsgesellschaft https://www.krebshilfe.de/fileadmin/Downloads/PDFs/Stellungnahmen/Prognos_Endbericht_Deutsche_Krebshilfe.pdf
    PubMed
  • 40 https://www.onkozert.de/organ/kopf-hals/
    PubMed
  • 41 Kowalski C, Graeven U, von Kalle C, Lang H, Beckmann MW, Blohmer JU, Burchardt M, Ehrenfeld M, Fichtner J, Grabbe S, Hoffmann H, Iro H, Post S, Scharl A, Schlegel U, Seufferlein T, Stummer W, Ukena D, Ferencz J, Wesselmann S. Shifting cancer care towards multidisciplinarity: the cancer center certification program of the German cancer society. BMC Cancer 2017; 17: 850
    CrossrefPubMedGoogle Scholar
  • 42 Oeser A, Gaebel J, Dietz A, Wiegand S, Oeltze-Jafra S. Information architecture for a patient-specific dashboard in head and neck tumor boards. Int J Comput Assist Radiol Surg 2018; 13: 1283-1290
    CrossrefPubMedGoogle Scholar
  • 43 Wiegand S, Dietz A. Vor- und Nachteile eines Zertifizierungsverfahrens aus Sicht eines Kopf-Hals-Tumorzentrums. Der Onkologe 2017; 23: 719-726
    CrossrefPubMedGoogle Scholar
  • 44 Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. NEJM 1979; 301: 1364-1369
    CrossrefPubMedGoogle Scholar
  • 45 Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747-1751
    CrossrefPubMedGoogle Scholar
  • 46 Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE. Hospital volume and surgical mortality in the United States. NEJM 2002; 346: 1128-1137
    CrossrefPubMedGoogle Scholar
  • 47 Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, Urbach DR, Goldstein DP. Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head Neck 2014; 36: 1820-1834
    CrossrefPubMedGoogle Scholar
  • 48 Eskander A, Irish J, Groome PA, Freeman J, Gullane P, Gilbert R, Hall SF, Urbach DR, Goldstein DP. Volume-outcome relationships for head and neck cancer surgery in a universal health care system. Laryngoscope 2014; 124: 2081-2088
    CrossrefPubMedGoogle Scholar
  • 49 Redmann AJ, Yuen SN, Von Allmen D, Rothstein A, Tang A, Breen J, Collar R. Does Surgical Volume and Complexity Affect Cost and Mortality in Otolaryngology-Head and Neck Surgery?. Otolaryngol Head Neck Surg 2019; 16: 194599819861524
    PubMedGoogle Scholar
  • 50 Cheung MC, Koniaris LG, Perez EA, Molina MA, Goodwin WJ, Salloum RM. Impact of hospital volume on surgical outcome for head and neck cancer. Ann Surg Oncol 2009; 16: 1001-1009
    CrossrefPubMedGoogle Scholar
  • 51 Lassig AA, Joseph AM, Lindgren BR, Fernandes P, Cooper S, Schotzko C, Khariwala S, Reynolds M, Yueh B. The effect of treating institution on outcomes in head and neck cancer. Otolaryngol Head Neck Surg 2012; 147: 1083-1092
    CrossrefPubMedGoogle Scholar
  • 52 Chen AY, Fedewa S, Pavluck A, Ward EM. Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer. Cancer 2010; 116: 4744-4752
    CrossrefPubMedGoogle Scholar
  • 53 Grover S, Swisher-McClure S, Mitra N, Li J, Cohen RB, Ahn PH, Lukens JN, Chalian AA, Weinstein GS, O'Malley Jr BW, Lin A. Total laryngectomy versus larynx preservation for T4a larynx cancer: Patterns of care and survival outcomes. Int J Radiat Oncol Biol Phys 2015; 92: 594-601
    CrossrefPubMedGoogle Scholar
  • 54 Luft HS, Hunt SS, Maerki SC. The volume-outcome relationship: practice-makes-perfect or selective-referral patterns?. Health Serv Res 1987; 22: 157-182
    PubMedGoogle Scholar
  • 55 Markar SR, Karthikesalingam A, Thrumurthy S, Low DE. Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011. J Gastrointest Surg 2012; 16: 1055-1063
    CrossrefPubMedGoogle Scholar
  • 56 Hoffmann H, Passlick B, Ukena D, Wesselmann S. Chirurgische Therapie des Lungenkarzinoms: Argumente für die Behandlung in großen Zentren. Zentralbl Chir 2019; 144: 62-70
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Trautmann F, Reissfelder C, Pecqueux M, Weitz J, Schmitt J. Evidence-based quality standards improve prognosis in colon cancer care. Eur J Surg Oncol 2018; 44: 1324-1330
    CrossrefPubMedGoogle Scholar
  • 58 Völkel V, Draeger T, Gerken M, Fürst A, Klinkhammer-Schalke M. Langzeitüberleben von Patienten mit Kolon und Rektumkarzinomen: Ein Vergleich von Darmkrebszentren und nicht zertifizierten Krankenhäusern. Gesundheitswesen 2018; Apr 19 DOI: 10.1055/a-0591-3827.. [Epub ahead of print]
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Lin CC, Lin HC. Effects of surgeon and hospital volume on 5-year survival rates following oral cancer resections: the experience of an Asian country. Surgery 2008; 143: 343-351
    CrossrefPubMedGoogle Scholar
  • 60 Broome M, Juilland N, Litzistorf Y, Monnier Y, Sandu K, Pasche P, Plinkert PK, Federspil PA, Simon C. Factors Influencing the Incidence of Severe Complications in Head and Neck Free Flap Reconstructions. Plast Reconstr Surg Glob Open 2016; 4: e1013
    CrossrefPubMedGoogle Scholar
  • 61 Morton RP, Gray L, Tandon DA, Izzard M, McIvor NP. Efficacy of neck dissection: are surgical volumes important?. Laryngoscope 2009; 119: 1147-1152
    CrossrefPubMedGoogle Scholar
  • 62 Cheraghlou S, Otremba M, Kuo Yu P, Agogo GO, Hersey D, Judson BL. Prognostic Value of Lymph Node Yield and Density in Head and Neck Malignancies. Otolaryngol Head Neck Surg 2018; 158: 1016-1023
    CrossrefPubMedGoogle Scholar
  • 63 de Kort WWB, Maas SLN. Van Es RJJ, Willems SM. Prognostic value of the nodal yield in head and neck squamous cell carcinoma: A systematic review. Head Neck 2019; 41: 2801-2810
    CrossrefPubMedGoogle Scholar
  • 64 Merz S, Timmesfeld N, Stuck BA, Wiegand S. Impact of Lymph Node Yield on Outcome of Patients with Head and Neck Cancer and pN0 Neck. Anticancer Res 2018; 38: 5347-5350
    PubMedGoogle Scholar
  • 65 Son H-J, Roh J-L, Cho K-J, Choi S-H, Nam SY, Kim SY. Nodal factors predictive of recurrence and survival in patients with oral cavity squamous cell carcinoma. Clin Otolaryngol 2017; 43: 470-476
    PubMedGoogle Scholar
  • 66 Divi V, Chen MM, Nussenbaum B, Rhoads KF, Sirjani DB, Holsinger FC, Shah JL, Hara W. Lymph node count from neck dissection predicts mortality in head and neck cancer. J Clin Oncol 2016; 34: 3892-3897
    CrossrefPubMedGoogle Scholar
  • 67 Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang QE, Le QT, Holsinger FC. Establishing quality indicators for neck dissection: correlating the number of lymph nodes with oncologic outcomes (NRG oncology RTOG 9501 and RTOG 0234). Cancer 2016; 122: 3464-3471
    CrossrefPubMedGoogle Scholar
  • 68 Böttcher A, Dommerich S, Sander S, Olze H, Stromberger C, Coordes A, Jowett N, Knopke S. Nodal yield of neck dissections and influence on outcome in laryngectomized patients. Eur Arch Oto-Rhino-Laryngology 2016; 273: 3321-3329
    PubMedGoogle Scholar
  • 69 Ebrahimi A, Clark JR, Amit M, Yen TC, Liao CT, Kowalski LP, Kreppel M, Cernea CR, Bachar G, Villaret AB, Fliss D, Fridman E, Robbins KT, Shah JP, Patel SG, Gil Z. Minimum nodal yield in oral squamous cell carcinoma: defining the standard of care in a multi-center international pooled validation study. Ann Surg Oncol 2014; 21: 3049-3055
    CrossrefPubMedGoogle Scholar
  • 70 Ebrahimi A, Zhang WJ, Gao K, Clark JR. Nodal yield and survival in oral squamous cancer. Cancer 2011; 117: 2917-2925
    CrossrefPubMedGoogle Scholar
  • 71 Landheer ML, Therasse P, van de Velde CJ. The importance of quality assurance in surgical oncology. Eur J Surg Oncol 2002; 28: 571e602
    PubMedGoogle Scholar
  • 72 Velanovich V, Rubinfeld I, Patton Jr JH, Ritz J, Jordan J, Dulchavsky S. Implementation of the national surgical quality improvement program: critical steps to success for surgeons and hospitals. Am J Med Qual 2009; 24: 474e9
    PubMedGoogle Scholar
  • 73 Birkmeyer JD, Shahian DM, Dimick JB, Finlayson SR, Flum DR, Ko CY, Hall BL. Blueprint for a new American College of Surgeons: National Surgical Quality Improvement Program. J Am Coll Surg 2008; 207: 777e82
    PubMedGoogle Scholar
  • 74 Lewis CM, Monroe MM, Roberts DB, Hessel AC, Lai SY, Weber RS. An audit in feedback system for effective quality improvement in head and neck surgery: can we become better surgeons?. Cancer 2015; 121: 1581-157
    CrossrefPubMedGoogle Scholar
  • 75 Liu JC, Kaplon A, Blackman E, Miyamoto C, Savior D, Ragin C. The impact of the multidisciplinary tumor board on head and neck cancer outcomes. Laryngoscope 2019; May 16 DOI: 10.1002/lary.28066.. [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 76 Ruhstaller T, Roe H, Thürlimann B, Nicoll JJ. The multidisciplinary meeting: An indispensable aid to communication between different specialities. Eur J Cancer 2006; 42: 2459-2462
    CrossrefPubMedGoogle Scholar
  • 77 Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK?. Lancet Oncol 2006; 7: 935-943
    CrossrefPubMedGoogle Scholar
  • 78 Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol 2011; 18: 2116-2125
    CrossrefPubMedGoogle Scholar
  • 79 Lamb BW, Sevdalis N, Vincent C, Green JSA. Development and evaluation of a checklist to support decision making in cancer multidisciplinary team meetings: MDT-QuIC. Ann Surg Oncol 2012; 19: 1759-6
    PubMedGoogle Scholar
  • 80 Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, Güresir E, Schröck A, Far F, Pietsch T, Pantelis D, Thomas D, Vornholt S, Ernstmann N, Manser T, Neumann M, Funke B, Schmidt-Wolf IGH. Cross-sectional increase of adherence to multidisciplinary tumor board decisions. BMC Cancer 2018; 18: 936
    CrossrefPubMedGoogle Scholar
  • 81 Faller H, Koch U, Brähler E, Härter M, Keller M, Schulz H, Wegscheider K, Weis J, Boehncke A, Hund B, Reuter K, Richard M, Sehner S, Szalai C, Wittchen HU, Mehnert A. Satisfaction with information and unmet information needs in men and women with cancer. J Clin Oncol 2016; 10: 62-70
    PubMedGoogle Scholar
  • 82 Baile WF, Buckmann R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES: a six-step protocol for delivering bad news – application to the patient with cancer. Oncologist 2000; 5: 302-311
    CrossrefPubMedGoogle Scholar
  • 83 Makoul G. Essential elements of communication in medical encounters: the Kalamazoo consensus statement. Acad Med 2001; 76: 390-393
    CrossrefPubMedGoogle Scholar
  • 84 Simpson M, Buckman R, Stewart M, Maguire P, Lipkin M, Novack D, Till J. Doctor-patient communication: the Toronto consensus statement. BMJ 1991; 303: 1385-1387
    CrossrefPubMedGoogle Scholar
  • 85 Albert US, Zemlin C, Hadji P, Ziller V, Kuhler B, Frank-Hahn B, Wagner U, Kalder M. The Impact of Breast Care Nurses on Patients’ Satisfaction, Understanding of the Disease, and Adherence to Adjuvant Endocrine Therapy. Breast Care (Basel). 2011. 6 221-226
    Google Scholar
  • 86 Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten https://www.awmf.org/uploads/tx_szleitlinien/032-051OLk_S3_ Psychoonkologische _Beratung_Behandlung_2014-01_abgelaufen.pdf
    PubMed
  • 87 Mehnert A, Brähler E, Faller H, Härter M, Keller M, Schulz H, Wegscheider K, Weis J, Boehncke A, Hund B, Reuter K, Richard M, Sehner S, Sommerfeldt S, Szalai C, Wittchen HU, Koch U. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 2014; 32: 3540-3546
    CrossrefPubMedGoogle Scholar
  • 88 Singer S, Krauss O, Keszte J, Siegl G, Papsdorf K, Severi E, Hauss J, Briest S, Dietz A, Brähler E, Kortmann RD. Predictors of emotional distress in patients with head and neck cancer. Head Neck 2012; 34: 180-187
    CrossrefPubMedGoogle Scholar
  • 89 Singer S, Dieng S, Wesselmann S. Psycho-oncological care in certified cancer centres – a nationwide analysis in Germany. Psycho-Oncol 2013; 22: 1435-1437
    CrossrefPubMedGoogle Scholar
  • 90 Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, Chen WH, Sridhara R, Farrell AT, Keegan P, Kim G, Pazdur R. Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. Clin Cancer Res 2016; 22: 1553-1558
    CrossrefPubMedGoogle Scholar
  • 91 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376
    CrossrefPubMedGoogle Scholar
  • 92 Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579
    CrossrefPubMedGoogle Scholar
  • 93 Duman-Lubberding S, van Uden-Kraan CF, Jansen F, Witte BI, Eerenstein SE, van Weert S, de Bree R, Leemans CR, Verdonck-de Leeuw IM. Durable usage of patient-reported outcome measures in clinical practice to monitor health-related quality of life in head and neck cancer patients. Support Care Cancer 2017; 25: 3775-3783
    CrossrefPubMedGoogle Scholar
  • 94 Duman-Lubberding S, van Uden-Kraan CF, Jansen F, Witte BI, van der Velden LA, Lacko M, Cuijpers P, Leemans CR, Verdonck-de Leeuw IM. Feasibility of an eHealth application “OncoKompas” to improve personalized survivorship cancer care. Support Care Cancer 2016; 24: 2163-2171
    CrossrefPubMedGoogle Scholar
  • 95 de Bree R, Verdonck-de Leeuw IM, Keizer AL, Houffelaar A, Leemans CR.. Touch screen computer-assisted health-related quality of life and distress data collection in head and neck cancer patients. Clin Otolaryngol 2008; 33: 138-142
    CrossrefPubMedGoogle Scholar
  • 96 Zebralla V, Pohle N, Singer S, Neumuth T, Dietz A, Stier-Jarmer M, Boehm A. Introduction of the Screening Tool OncoFunction for Functional Follow-up of Head and Neck Patients. Laryngorhinootol 2016; 95: 118-124
    PubMedGoogle Scholar
  • 97 Matthijs de Wit L, van Uden-Kraan CF, Lissenberg-Witte BI, Melissant HC, Fleuren MA, Cuijpers P, Verdonck-de Leeuw IM. Adoption and implementation of a web-based self-management application “Oncokompas” in routine cancer care: A national pilot study. Support Care Cancer 2019; 27: 2911-2920
    CrossrefPubMedGoogle Scholar
  • 98 U.S. Food and drug administration (FDA) . Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Federal Regist 2006; 74: 65132-65133
    PubMedGoogle Scholar
  • 99 Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA J Am Med Assoc 2017; 318: 197-198
    CrossrefPubMedGoogle Scholar
  • 100 Holch JW, Westphalen CB, Hiddemann W, Heinemann V, Jung A, Metzeler KH. Präzisionsonkologie und molekulare und molekulare Tumorboards-Konzepte, Chancen und Herausforderungen. Dtsch Med Wochenschr 2017; 142: 1676-1684
    Article in Thieme ConnectPubMedGoogle Scholar
  • 101 Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 2017; 19: 4-23
    CrossrefPubMedGoogle Scholar
  • 102 Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding KV, Nikiforova MN. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels. J Mol Diagn 2017; 19: 341-365
    CrossrefPubMedGoogle Scholar
  • 103 Cancer Genome Atlas Network . Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517: 576-582
    CrossrefPubMedGoogle Scholar
  • 104 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz Jr LA. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520
    CrossrefPubMedGoogle Scholar
  • 105 Drilon A, Laetsch TW, Kummar S. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378: 731-739
    CrossrefPubMedGoogle Scholar
  • 106 Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key lessons learned from Moffitt’s molecular tumor board: The clinical genomics action committee experience. Oncologist 2017; 22: 144-151
    CrossrefPubMedGoogle Scholar
  • 107 Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. Jama Oncol 2016; 2: 1452-1459
    CrossrefPubMedGoogle Scholar
  • 108 Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR. Experience with precision genomics and tumorboard, indicates frequent target identification, but barriers to delivery. Oncotarget 2017; 8: 27145-27154
    CrossrefPubMedGoogle Scholar
  • 109 Hirshfield KM, Tolkunov D, Zhong H. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. The Oncologist 2016; 21: 1315-1325
    CrossrefPubMedGoogle Scholar
  • 110 Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 2015; 33: 2753-2762
    CrossrefPubMedGoogle Scholar
  • 111 Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Broaddus R, Mills Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F. Clinical Use of Precision Oncology Decision Support. JCO Precis. Oncol. 2017; 2017
    PubMedGoogle Scholar
  • 112 Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X. SHIVA investigators. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16: 1324-1334
    CrossrefPubMedGoogle Scholar
  • 113 https://www.cancer.gov/news-events/press-releases/2018/nci-match-first-results
    PubMed
  • 114 Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol 2015; 33: 3817-3825
    CrossrefPubMedGoogle Scholar
  • 115 Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol 2018; 4: 1093-1098
    CrossrefPubMedGoogle Scholar
  • 116 Rieke DT, Leyvraz S, Burock S, Keilholz U. A comparison of treatment recommendations by molecular tumor boards worldwide. Ann Oncol 2017; 28 Issue suppl_5, mdx363.059 DOI: https://doi.org/10.1093/annonc/mdx363.059.
    CrossrefPubMedGoogle Scholar
  • 117 Kurnit KC, Bailey AM, Zeng J, Johnson AM, Shufean MA, Brusco L, Litzenburger BC, Sánchez NS, Khotskaya YB, Holla V, Simpson A, Mills GB, Mendelsohn J, Bernstam E, Shaw K, Meric-Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES. Implementation and utilization of the molecular tumor board to guide precision medicine. Oncotarget 2017; 8: 57845-57854
    CrossrefPubMedGoogle Scholar
  • 118 Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 2018; 29: 1895-1902
    CrossrefPubMedGoogle Scholar
  • 119 Naredi P, La Quaglia MP. The future of trials in surgical oncology. Nat Rev Clin Oncol 2015; 12: 425e31
    PubMedGoogle Scholar
  • 120 Ferris RL, Blumenschein Jr G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375: 1856-1867
    CrossrefPubMedGoogle Scholar
  • 121 Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ. KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019; 393: 156-167
    CrossrefPubMedGoogle Scholar
  • 122 Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro Jr. G. et al. Ann Oncol 2018; 29 (Suppl 8): Abstract LBA8_PR
    PubMed
  • 123 Schulz KF, Altman DG, Moher D. Group CONSORT. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Int J Surg 2011; 9: 672-677
    CrossrefPubMedGoogle Scholar
  • 124 Clavien PA, Lillemoe KD. A new policy to implement CONSORT guidelines for surgical randomized controlled trials. Ann Surg 2014; 260: 947e8
    PubMedGoogle Scholar
  • 125 Carlton DA, Kocherginsky M, Langerman AJ. A systematic review of the quality of randomized controlled trials in head and neck oncology surgery. Laryngoscope 2015; 125: 146-152
    CrossrefPubMedGoogle Scholar
  • 126 Therasse P, De Mulder PH. Quality assurance in medical oncology within the EORTC. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002; 38 (Suppl 4) 152-154
    CrossrefPubMedGoogle Scholar
  • 127 Weber DC, Poortmans PM, Hurkmans CW, Aird E, Gulyban A, Fairchild A. Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting. Radiother Oncol 2011; 100: 150-156
    CrossrefPubMedGoogle Scholar
  • 128 Budiharto T, Musat E, Poortmans P, Hurkmans C, Monti A, Bar-Deroma R, Bernstein Z. Tienhoven Gv, Collette L, Duclos F, Davis B, Aird E; EORTC Radiation Oncology Group. Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. Radiother Oncol 2008; 88: 403-410
    CrossrefPubMedGoogle Scholar
  • 129 Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. EORTC Head and Neck Cancer Cooperative group. J Natl Canc Inst 1996; 88: 890e9
    PubMedGoogle Scholar
  • 130 Evrard S, Audisio R, Poston G, Caballero C, Kataoka K, Fontein D, Collette L, Nakamura K, Fukuda H, Lacombe D. From a comic opera to surcare an open letter to whom clinical research in surgery is a concern: announcing the launch of SURCARE. Ann Surg 2016; 264: 911e2
    PubMedGoogle Scholar
  • 131 Simon C, Caballero C, Gregoire V, Thurnher D, Koivunen P, Ceruse P, Spriano G, Nicolai P, Licitra L, Machiels JP, Hamoir M, Andry G, Mehanna H, Hunter KD, Dietz A, Leemans CR. Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 ‘Best of’ and 24954 ‘larynx preservation’ study. Eur J Cancer 2018; 103: 69-77
    CrossrefPubMedGoogle Scholar
  • 132 Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 2015; 33: 156-164
    PubMedGoogle Scholar
  • 133 Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, Kölbl O, Hautmann MG, Strutz J, Schreiber F, Bockmühl U, Schilling V, Feyer P, de Wit M, Maschmeyer G, Jungehülsing M, Schroeder U, Wollenberg B, Sittel C, Münter M, Lenarz T, Klussmann JP, Guntinas-Lichius O, Rudack C, Eich HT, Foerg T, Preyer S, Westhofen M, Welkoborsky HJ, Esser D, Thurnher D, Remmert S, Sudhoff H, Görner M, Bünzel J, Budach V, Held S, Knödler M, Lordick F, Wiegand S, Vogel K, Boehm A, Flentje M, Keilholz U. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol 2018; 29: 2105-2114
    CrossrefPubMedGoogle Scholar
  • 134 Grègoire V, Lefebvre JL, Licitra L, Felip E. Group . EHNS-ESMO-ESTRO Guidelines Working. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5) v184-v186
    CrossrefPubMedGoogle Scholar
  • 135 Zebralla V, Meuret S, Wiegand S. Monitoring and Evaluation of Late Functional Outcome in Post-treatment Follow-Up in Clinical Routine Setting. Front Oncol 2019; 9: 700
    CrossrefPubMedGoogle Scholar
  • 136 Zebralla V, Kaminski K, Wichmann G, Dietz A, Wiegand S. Rückkehr in das Erwerbsleben nach kurativer Therapie von Kopf-Hals-Karzinomen. Laryngorhinootologie 2018; 97: 838-845
    Article in Thieme ConnectPubMedGoogle Scholar
  • 137 Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Otol Hematol 2011; 77: 109-130
    PubMedGoogle Scholar
  • 138 Mehnert A, Barth J, Gaspar M, Leibbrand B, Kegel CD, Bootsveld W, Friedrich M, Hartung TJ, Berger D, Koch U. Predictors of early retirement after cancer rehabilitation-a longitudinal study. Eur J Cancer Care (Engl) 2017; 26: 5
    PubMedGoogle Scholar
  • 139 Böttcher HM, Steimann M, Koch U, Bergelt C. Return to work – experiences and expectations of cancer patients during inpatient rehabilitation. Rehabilitation 2012; 51: 31-38
    Article in Thieme ConnectPubMedGoogle Scholar
  • 140 Broemer L, Esser P, Koranyi S, Friedrich M, Leuteritz K, Wiegand S, Dietz A, Boehm A, Pabst F, Strauß BM, Guntinas-Lichius O, Mehnert A. Machbarkeit einer Gruppenintervention zur Förderung der Arbeitsfähigkeit für Patienten mit Kopf-Hals-Tumoren. Laryngorhinootol 2019; 98: 175-182
    Article in Thieme ConnectPubMedGoogle Scholar